Gilead Sciences (GILD) share buybacks: $1.9B
Gilead Sciences spent $1.9B buying back its own shares in the year ended Dec 31, 2025, up 67.1% from $1.1B a year earlier.
From Gilead Sciences's filings with the SEC · Read the filing · GILD stock page
Gilead Sciences share buybacks by year
#118 of 1,890 US companies by share buybacks · See the full ranking
| Year ended | Share buybacks | Change |
|---|---|---|
| Dec 31, 2025 | $1.9B | +67% |
| Dec 31, 2024 | $1.1B | +15% |
| Dec 31, 2023 | $1B | -28% |
| Dec 31, 2022 | $1.4B | +156% |
| Dec 31, 2021 | $546M | – |
Share buybacks of similar companies
Companies in the same industry as Gilead Sciences, by SEC industry code, with the closest share buybacks. Each name opens the same page for that company.
| Company | Share buybacks, latest year | Year ended |
|---|---|---|
| Gilead Sciences | $1.9B | Dec 31, 2025 |
| Exelixis | $948M | Jan 2, 2026 |
| Halozyme Therapeutics | $342M | Dec 31, 2025 |
| Qiagen | $280M | Dec 31, 2025 |
| Neurocrine Biosciences | $168M | Dec 31, 2025 |
| BIO-TECHNE | $41.7M | Jun 30, 2026 |
| ADMA Biologics | $31.9M | Dec 31, 2025 |
Questions and answers
What is Gilead Sciences's share buybacks?
Gilead Sciences spent $1.9B buying back its own shares in the year ended Dec 31, 2025, up 67.1% from $1.1B a year earlier.
Numbers as reported in Gilead Sciences's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology